Alzheimer’s Therapeutics Market

The Alzheimer’S Therapeutics Market Size Was Valued At USD 4.85 Billion In 2023 And Is Estimated To Reach USD 24.66 Billion By 2032. It Is Anticipated To Grow At A Compound Annual Growth Rate (CAGR) Of 19.8% From 2024 To 2032.

A neurological condition called Alzheimer’s disease results in the death of brain cells and brain shrinkage. It is the most prevalent form of dementia that causes a person’s capacity to function independently to continuously deteriorate in their mental, behavioral, and social abilities. The disease’s early symptoms include forgetting recent conversations or experiences. As the disease advances, a person with Alzheimer’s will have severe memory loss and lose the capacity to do daily duties.

The prevalence of Alzheimer’s disease is increasing in both developed and developing nations, which is a major factor driving the growth of the global market for Alzheimer’s therapies. The demand for developing therapies for Alzheimer’s disease has also increased due to the rising incidence of the condition around the world and a few other factors, such as an increase in the number of individuals who have been diagnosed. The availability of medications like Aricept, Exelon, Memantine, and Razadyne for the treatment of Alzheimer’s disease is another factor driving the market’s expansion. Additionally, according to an article by NCBI from 2019, there were 121,499 Alzheimer ‘s-related fatalities in the United States. As a result of the increase in Alzheimer’s disease instances, the demand for treatments has increased, which has greatly fueled the market’s expansion.

Market Dynamics

Market expansion is anticipated to be fueled by the increasing prevalence of Alzheimer’s disease and the approval of disease-modifying treatments. According to the NCBI, there were around 6.7 million Americans 65 and older who had Alzheimer’s disease in 2023; this number is predicted to rise to almost 13.8 million by 2060. Due to their greater life expectancy, women are more likely than men to be diagnosed with Alzheimer’s disease. Additionally, Alzheimer’s disease is quickly overtaking other neurodegenerative illnesses as the leading cause of death and a major contributor to physical impairment that calls for urgent medical attention.

Pharmaceutical businesses will benefit from the launch of new, very sensitive cloud-based cognitive evaluation technologies for identifying drug effects in patients. Pharmaceutical firms can use this information to assess the safety and cognitive efficacy of potential AD treatments. The Cantab Connect tool from Cambridge Cognition was created especially for evaluating the efficacy of medications being made for mild, moderate, and prodromal AD. The market for AD treatments will grow due to the use of this technology, which will improve the chance of product approvals.

Due to stringent government actions like lockdowns to stop the spread of infection, the COVID-19 pandemic hurt the market. Due to decreased patient visits to clinics and hospitals for treatment and concern for COVID-19 infection, the prescription rate for medications used to treat Alzheimer’s was reduced during the pandemic, which inhibited market expansion.

There are few other available treatments due to the uncertainty, failure, and cessation of Alzheimer’s drug clinical studies. The price of research and development goes up as a result. Consequently, it is anticipated to limit market expansion.

Market Segmentation

Product Overview

Cholinesterase inhibitors emerged as the leading segment in 2023, capturing a significant revenue share of over 50.24%. This category represents the standard treatment for Alzheimer’s, with notable developments such as the FDA approval of Adlarity (donepezil hydrochloride) by Corium Inc. in March 2022. Modularity, a transdermal patch delivering a stable dose of donepezil, offers a weekly administration option, enhancing patient convenience. The market segments further include NMDA receptor antagonists, combination drugs, and promising pipeline drugs.

Pipeline Expansion
The pipeline drugs segment is poised for rapid growth, driven by the anticipated launches of several disease-modifying therapies. Notable pharmaceutical companies like F. Hoffmann La Roche Ltd., Biogen/Eisai Inc., and Eli Lilly and Company are advancing drug candidates that promise to reshape Alzheimer’s treatment. With 143 drug candidates in 172 clinical trials, including 31 in phase 3 trials, 82 in phase 2, and 30 in phase 1, the successful development and approval of these therapies are expected to significantly drive market expansion.

End-user Dynamics

In 2022, hospital pharmacies dominated the market with a share exceeding 57.07%, attributed to increased hospitalizations among the aging population afflicted with Alzheimer’s. Despite this dominance, the e-commerce segment is poised for substantial growth, fueled by rising internet and smartphone usage facilitating convenient medication procurement. The global expansion of e-commerce services further enhances growth prospects in this segment.

Regional Trends

North America emerged as the dominant market in 2022, with a share surpassing 40.79%, driven by extensive research efforts and governmental support for Alzheimer’s treatment. Noteworthy breakthroughs include the FDA’s designation of lecanemab (BAN2401) by Eisai Co., Ltd., and Biogen as a Breakthrough Therapy. In contrast, the Asia Pacific region is poised for rapid growth, fueled by increasing awareness and research initiatives to develop novel Alzheimer’s treatments, particularly in countries like Australia, where dementia prevalence is rising.

Key Players and Strategies

Key players in the Alzheimer’s therapeutics market are focusing on new product launches and substantial R&D investments to bolster their market presence. For example, Eisai Co., Ltd. received FDA approval for Leqembi (lecanemab-irmb) in January 2023, showcasing advancements in Alzheimer’s treatment. Leading companies driving innovation in the market include Novartis AG, AbbVie Inc. (Allergan Plc.), and Biogen, among others, aiming to address the growing demand for effective Alzheimer’s therapeutics.

Key players in the worldwide Alzheimer’s therapeutics market comprise:

1. Eisai Co., Ltd.
2. Novartis AG
3. AbbVie Inc. (Allergan Plc.)
4. Adamas Pharmaceuticals, Inc.
5. H. Lundbeck A/S
6. Biogen
7. AC Immune
8. F. Hoffmann La Roche Ltd.
9. Daiichi Sankyo Company, Limited
10. Johnson & Johnson Services, Inc.
11. TauRx Pharmaceuticals Ltd.

Recent Development:

• The collaboration agreement between Biogen Inc. and Eisai Co., Ltd. on Aducanumab, a medication for Alzheimer’s disease that is sold as ADUHELM® in the US, has been revised, the firms announced in March 2022.

 Alzheimer’s Therapeutics Market Report Scope

Global Alzheimer’s Therapeutics Market Report Segmentation

This report projects revenue growth and offers an analysis of the latest trends in each of the sub-segments spanning from 2018 to 2032. For this report, Beyond Market Insights has segmented the global Alzheimer’s therapeutics market based on product, end-user, and region:

Product Outlook (Revenue, USD Million, 2018 – 2032)

1. Cholinesterase Inhibitors
   • Donepezil
   • Galantamine
   • Rivastigmine
2. NMDA Receptor Antagonist
3. Combination Drug
4. Pipeline Drugs

End-user Outlook (Revenue, USD Million, 2018 – 2032)

1. Hospital Pharmacy
2. Retail Pharmacy
3. E-commerce

Regional Outlook (Revenue, USD Million, 2018 – 2032)

1. North America
   • U.S.
   • Canada
2. Europe
   • Germany
   • U.K.
   • Spain
   • France
   • Italy
   • Denmark
   • Sweden
   • Norway
3. Asia Pacific
   • Japan
   • China
   • India
   • South Korea
   • Thailand
   • Australia
4. Latin America
   • Brazil
   • Mexico
   • Argentina
5. MEA (Middle East & Africa)
   • South Africa
   • Saudi Arabia
   • UAE
   • Kuwait

Related Reports

• Osteoarthritis Therapeutics Market
• Active Pharmaceutical Ingredients Market
• Air Ambulance Services Market
• Antiseptics and Disinfectants Market